Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Asaf Alimardanov"'
Autor:
Resat Cinar, Joshua K. Park, Charles N. Zawatsky, Nathan J. Coffey, Steven P. Bodine, Jasmina Abdalla, Tadafumi Yokoyama, Tony Jourdan, Lindsey Jay, Mei Xing G. Zuo, Kevin J. O'Brien, Junfeng Huang, Ken Mackie, Asaf Alimardanov, Malliga R. Iyer, William A. Gahl, George Kunos, Bernadette R. Gochuico, May Christine V. Malicdan
Publikováno v:
Clinical and Translational Medicine, Vol 11, Iss 7, Pp n/a-n/a (2021)
Abstract Hermansky–Pudlak syndrome (HPS) is a rare genetic disorder which, in its most common and severe form, HPS‐1, leads to fatal adult‐onset pulmonary fibrosis (PF) with no effective treatment. We evaluated the role of the endocannabinoid/C
Externí odkaz:
https://doaj.org/article/6b58354bc8cd41de976ad8a5c91da796
Autor:
Ramarao Vepachedu, Trevor Broadt, Peter Pechan, Brian Bowser, Nora Yang, George Mitra, Asaf Alimardanov, Samir Hussein Shaban, Jenna Burns, Nagarathinam Selvaraj, Chao-Kuei Wang, Nirmala Saptharishi, Diane Golebiowski
Publikováno v:
Hum Gene Ther
Recombinant adeno-associated viral (rAAV) vector-based gene therapy has been adapted for use in more than 100 clinical trials. This is mainly because of its excellent safety profile, ability to target a wide range of tissues, stable transgene express
Autor:
Jessica Weant, David D. Eveleth, Amuthakannan Subramaniam, Jennifer Jenkins-Eveleth, Michael Blaber, Ling Li, David M. Ornitz, Asaf Alimardanov, Trevor Broadt, Hui Dong, Vinay Vyas, Xiaoyi Yang, Ralph A. Bradshaw
Publikováno v:
Growth Factors. 39:14-27
Utilising rabbit corneal endothelial cells (CEC) in three different paradigms, two human FGF1 derivatives (TTHX1001 and TTHX1114), engineered to exhibit greater stability, were tested as proliferative agents. Primary CECs and mouse NIH 3T3 cells trea
Autor:
Elizabeth A. Ottinger, Anne Pariser, Philip J. Brooks, Asaf Alimardanov, Christopher P. Austin, Richa Madan Lomash, Eric Esposito, Pramod S. Terse, Carsten G. Bönnemann, Xin Xu, Deanna Portero, Randy J. Chandler, Janelle Geist Hauserman, Charles P. Venditti, Donald C. Lo
Publikováno v:
Human Gene Therapy
Autor:
George Kunos, Lindsey Jay, Charles N. Zawatsky, Resat Cinar, Ken Mackie, Joshua K. Park, Bernadette R. Gochuico, Mei Xing G. Zuo, Asaf Alimardanov, Steven P. Bodine, Tadafumi Yokoyama, Junfeng Huang, Nathan J. Coffey, Kevin J. O'Brien, William A. Gahl, May Christine V. Malicdan, Tony Jourdan, Malliga R. Iyer, Jasmina Abdalla
Publikováno v:
Clinical and Translational Medicine
Clinical and Translational Medicine, Vol 11, Iss 7, Pp n/a-n/a (2021)
Clinical and Translational Medicine, Vol 11, Iss 7, Pp n/a-n/a (2021)
Hermansky–Pudlak syndrome (HPS) is a rare genetic disorder which, in its most common and severe form, HPS‐1, leads to fatal adult‐onset pulmonary fibrosis (PF) with no effective treatment. We evaluated the role of the endocannabinoid/CB1R syste
Publikováno v:
J Agric Food Chem
Creatine transporter deficiency (CTD) is caused by a defect in the X-linked creatine transporter SLC6A8 gene leading to severe neurologic and physiologic conditions. Cyclocreatine and phosphocyclocreatine supplementation is seen as a potential treatm
Autor:
Hongyan Xu, Amy Wang, Asaf Alimardanov, Jose Sangerman, Xin Xu, London Toney, Gregory J. Tawa, Levi Makala, Susan P. Perrine, Roman F. Wolf, Aidan D. Faller, Betty S. Pace, Mayuko Takezaki, Wei Zheng, Junfeng Huang, Biaoru Li, Sharie J. Haugabook
Publikováno v:
Blood Cells Mol Dis
Increased expression of developmentally silenced fetal globin (HBG) reduces the clinical severity of β-hemoglobinopathies. Benserazide has a relatively benign safety profile having been approved for 50 years in Europe and Canada for Parkinson's dise
Autor:
Betty S. Pace, Hanny Al-Samkari, Sujit Sheth, Abdullah Kutlar, Xin Xu, Pramod S. Terse, Seyed Mehdi Nouraie, Susan P. Perrine, Aidan D Faller, Kevin H.M. Kuo, Sharie J. Haugabook, Sylvia Titi Singer, Arthur J. Sytkowski, Franciscus A. Kuypers, Haksong Jin, Gershwin Blyden, Lanetta Bronté-Hall, Asaf Alimardanov
Publikováno v:
Blood. 138:4159-4159
Increased expression of fetal globin (HBG) has been shown to reduce clinical severity of beta-globin disorders and increase survival in sickle cell disease (SCD), through improved globin chain balance in beta thalassemia and reduced HbS polymerizatio
Autor:
Thomas F. Patterson, Edward P. Garvey, Nathan P. Wiederhold, William J. Hoekstra, Amy Wang, Elizabeth A. Ottinger, Robert J. Schotzinger, Xin Xu, Jim Cradock, Marcos Olivo, Rosie Jaramillo, Laura K. Najvar, Mark Behnke, William R. Kirkpatrick, Stephen Brand, Asaf Alimardanov
VT-1129 is a novel fungal enzyme-specific Cyp51 inhibitor with potent cryptococcal activity. Because of its long half-life (>6 days in mice) and our desire to quickly reach potent efficacy, we evaluated a VT-1129 loading dose-maintenance dose strateg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09d9ee21373afd31307cacd678ea123b
https://europepmc.org/articles/PMC6201077/
https://europepmc.org/articles/PMC6201077/
Autor:
Thomas F. Patterson, William J. Hoekstra, Stephen Brand, Rosie Jaramillo, Elizabeth A. Ottinger, William R. Kirkpatrick, Edward P. Garvey, Jim Cradock, Nathan P. Wiederhold, Asaf Alimardanov, Xin Xu, Marcos Olivo, Robert J. Schotzinger, Mark Behnke, Laura K. Najvar
Publikováno v:
Antimicrobial Agents and Chemotherapy. 62
Cryptococcal meningitis is a significant cause of morbidity and mortality in immunocompromised patients. VT-1129 is a novel fungus-specific Cyp51 inhibitor with potent in vitro activity against Cryptococcus species. Our objective was to evaluate the